Phase II trial of vorinostat in advanced melanoma
Haas, N. B., Quirt, I., Hotte, S., McWhirter, E., Polintan, R., Litwin, S., Adams, P. D., McBryan, T., Wang, L., Martin, L. P., vonMehren, M., Alpaugh, R. K., Zweibel, J., Oza, A.
Published in Investigational new drugs (01.06.2014)
Published in Investigational new drugs (01.06.2014)
Get full text
Journal Article
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia
Mackay, H.J, Buckanovich, R.J, Hirte, H, Correa, R, Hoskins, P, Biagi, J, Martin, L.P, Fleming, G.F, Morgan, R, Wang, L, Polintan, R, Oza, A.M
Published in Gynecologic oncology (01.04.2012)
Published in Gynecologic oncology (01.04.2012)
Get full text
Journal Article
Phase II study of vorinostat in patients with advanced melanoma
Haas, N. B., McWhirter, E., Hogg, D., Martin, L. P., Polintan, R., Litwin, S., Wang, L., Alpaugh, R. K., Zwiebel, J. A., Oza, A. M.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article
A phase II study of aflibercept (VEGF trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: A study of the Princess Margaret Hospital Phase II Consortium
Townsley, C., Hirte, H., Hoskins, P., Buckanovich, R., Mackay, H., Welch, S., Wang, L., Polintan, R., Chen, A., Oza, A. M.
Published in Journal of clinical oncology (20.05.2009)
Published in Journal of clinical oncology (20.05.2009)
Get full text
Journal Article